The COVID-19 epidemic has slowed the global movement of people, goods, and services, disrupted supply chains, limited sales operations, marketing activities, customer field assistance, and slowed product shipment and delivery. As a result, several firms' sales of sequencing consumables, sequencing services, and equipment services are expected to fall in 2020. However, as governments increasingly loosen travel restrictions, there is a rebound in testing numbers. With the COVID-19 pandemic, dealing with infectious illnesses has become a major medical concern throughout the world. Aside from vaccinations and therapeutic medications, there is an increasing demand for more accurate and easy testing methods as well as the expansion of testing structures.The Global Next-Generation Sequencing Services market was valued at USD 1.19 billion in 2021 and it is predicted to reach USD 4.55 billion by 2030, rising at a compound annual growth rate (CAGR) of 18.3 % from 2022 to 2030.
NGS stands for next-generation sequencing, which is a massively parallel sequencing technology that provides ultra-high throughput, scalability, and speed. The method is used to identify the nucleotide order of whole genomes or specific DNA or RNA portions. NGS has changed biology, allowing laboratories to undertake a wide range of applications and analyse biological systems at a level never previously feasible.
Years Considered for the study:
Next-Generation Sequencing Services Market
By Product & Service Type:
Consumables, platforms, and services are the three product categories in the market. It is further divided into sample preparation consumables and other consumables depending on consumables. DNA fragmentation, end-repair, A-Tailing & size selection, library preparation & target enrichment, and quality control are the several types of sample preparation consumables.
By Technology Outlook:
With a revenue share of approximately 35% in 2021, targeted sequencing and resequencing dominated the NGS industry. The method provides cost-effective alternatives to WGS and allows for a more in-depth analysis of genomic areas. Because of the growing demand for differential expression analysis, RNA-based targeted sequencing is expected to rise rapidly in the next years.From 2022 to 2030, the WGS technology is expected to increase at a high rate. The usage of WGS to fight Covid-19 has increased due to sector expansion. Furthermore, businesses like Illumina provide microbial WGS as the first NGS approach for infectious disease surveillance on the market.
By Application Outlook:
In 2021, the others category dominated the next-generation sequencing market. In 2021, cardiovascular surgery had the second-largest revenue share. This is due to the high prevalence of cardiac disorders, the availability of enough experts in the field, favourable reimbursement conditions, and technological advancements in diagnostics. This is resulting in a large increase in the number of cardiac procedures, which is driving up demand for the Next-Generation Sequencing Market over the forecast period. Also, orthopaedic surgery was the third-largest application segment, and it is predicted to grow at a healthy rate during the forecast period. This is due to an increase in the frequency of road accidents, which is leading to an increase in orthopaedic injuries. According to the US Department of Transportation, in the first half of 2021, an expected 20,160 persons died in motor vehicle accidents.
By End-user Outlook:
In 2020, the academic research end-user category had the biggest share, accounting for more than 53%. From 2022 to 2030, the category is expected to grow at a stable CAGR. This expansion might be linked to the use of NGS solutions in research initiatives conducted by universities and research institutions. Furthermore, scholarships for NGS PhD studies are expected to boost demand for NGS goods and services, resulting in profitable development in the coming years.
Furthermore, nations such as Germany and the United Kingdom have a number of institutions that offer NGS and molecular biology courses. The Wageningen University & Research in the Netherlands, for example, has NGS facilities and technology that may be used for a variety of applications.
By Regional Outlook:
Within North America, the United States is predicted to have a significant share of the market, and this trend is expected to continue in the future years. With the COVID-19 pandemic in this region, next-generation sequencing (NGS) technology is gaining prominence as a regular clinical diagnostic tool. The industry's expansion is aided by an increase in the number of strategic advances made by the region's main market participants.
For example, Helix Laboratory's COVID-19 NGS test, which is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative identification of nucleic acid from the SARS-CoV-2 in upper respiratory specimens for COVID-19 suspected persons, gained FDA clearance in August 2020.
By Key Competitors and Market Share Analysis:
The market is slightly consolidated, with a few large companies accounting for the majority of revenue. The major businesses are concentrating their efforts on launching new items that will help them gain a firm foothold in the industry.
The industry is characterised by fierce rivalry among the major companies. The creation of innovative platforms that are fast, small, and less expensive is one of the strategies used by these firms to improve their market position.
The following are some of the major market players operating across the globe:
- Thermo Fisher Scientific, Inc.
- F. Hoffman-La Roche Ltd.
- Oxford Nanopore Technologies
- Genomatix GmbH
- DNASTAR, Inc.
- Eurofins GATC Biotech GmbH
- Perkin Elmer, Inc.
- Bio-Rad Laboratories, Inc.
Scope of the report
|Actual estimates/Historical data||2017 - 2020|
|Forecast period||2022 - 2030|
|Market representation||Revenue in USD 4.55 billion & 18.3% CAGR from 2022 to 2030|
|Regional scope||North America, Europe, Asia Pacific, Latin America, MEA|
|Country scope||USA, Canada, Mexico, Brazil, Argentina, U.K., Germany, Italy, France, Spain, China, Japan, South Korea, India, Australia, Saudi Arabia, Qatar, UAE, South Africa, etc.|
|The Segment covered by||Product & Service, Application, End User|
|Companies covered||Illumina, QIAGEN, Thermo Fisher Scientific, Inc., F. Hoffman-La Roche Ltd., Oxford Nanopore Technologies, Genomatix GmbH, PierianDx, DNASTAR, Inc., Eurofins GATC Biotech GmbH, Perkin Elmer, Inc., BGI, Bio-Rad Laboratories, Inc.|
|Report coverage||Revenue forecast, company share, competitive landscape, growth factors, and trends|
|Free customization scope (equivalent to 5 analyst working days)||If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of the customization|
Major Highlights and USPs of Report:
- Detailed look Revenue, Sales and Production Analysis by Region/Country
- Company Market Share Analysis for 5 Years, Revenue, Sales, Price, and Gross Margin Analysis
- Porter Five Forces Analysis
- Market Dynamics (Driver, Restrain and Opportunities Analysis)
- Value Chain Analysis
- Porter Five Force Model
- Pestle Analysis
- Regulatory Framework
- Technology Roadmap
- The Market attractiveness analysis of each segment
- Marketing Strategy Analysis
- Direct Marketing
- Indirect Marketing
- Country Level Analysis
- Raw Material Analysis
- Cost Structure
- Recent Initiative by Key Players to Sustain in Competition
Available Array of Customizations:
- Country-level bifurcation of data for any specific regional/country-specific report.
- Enlargement of scope and data forecasts until 2030.
- Company Market Share for specific country/countries and regions.
- Customized Report Framework for Go-To-Market Strategy.
- Customized Report Framework for Merger & Acquisitions and Partnerships/JVs Feasibility.
- Customized Report Framework for particular Type/ Application/ New Product/Services Launch and/or Development.
- Detailed Report and Deck for any specific Company operating in the Industry competitors.
- Any other miscellaneous requirements with feasibility analysis.
Segments Covered in the Report
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2030. For the purpose of this report, Data Lab Forecast has segmented the global Next-Generation Sequencing Services Market report on the basis of Product & Service, Application, End User, and region:
The report segment of the global Next-Generation Sequencing Services market is as follows:
Global Next-Generation Sequencing Services Market: By Product & Service Outlook (Revenue, USD Million, 2021 - 2030)
Global Next-Generation Sequencing Services Market: By Application Outlook (Revenue, USD Million, 2021 - 2030)
- Drug Discovery
Global Next-Generation Sequencing Services Market: By End User Outlook (Revenue, USD Million, 2021 - 2030)
Global Next-Generation Sequencing Services Market: By Region Outlook (Revenue, USD Million, 2021 - 2030)
In case you dont find what you are looking for, please get in touch with our custom research team at email@example.com
- North America
- The U.S.
- Rest of North America
- Rest of Europe
- Asia Pacific
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- The Middle East and Africa
- GCC Countries
- South Africa
- Rest of The Middle East & Africa